Glaucoma, a leading cause of blindness, demands innovative management strategies. Glaucoma: New therapies and surgical techniques explore minimally invasive glaucoma surgeries (MIGS), such as trabecular meshwork stents, which offer safer alternatives to traditional procedures. Novel pharmacological agents, including rho kinase inhibitors, enhance trabecular outflow, reducing intraocular pressure. Sustained-release drug delivery systems promise improved patient compliance. Diagnostic advancements, like optical coherence tomography angiography, enable earlier detection of optic nerve damage. These developments allow personalized treatment plans, balancing efficacy and safety. Surgeons are adopting laser-based techniques, such as selective laser trabeculoplasty, for precise pressure control. Continuous research and clinical trials are critical to refining these approaches, ensuring better outcomes for patients at risk of vision loss.







Title : Lenadogene nolparvovec gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom